VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”)…
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE…
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving…
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 12, 2024 /PRNewswire/ -- USA News Group News Commentary – The…
IRVINE, Calif., Dec. 12, 2024 /PRNewswire/ -- MaxScientific Inc., a global leader in the field of aging and longevity intervention,…
CDMO's Cell and Gene Center of Excellence Achieves fifth commercial viral vector product approval, and second overall from FDA in…
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for…
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth…
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage…
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug,…